Standout Papers
- Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib (2015)
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial (2018)
- Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia (2022)
- Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort (2022)
Citation Impact
3 from Science/Nature 65 standout
Citing Papers
Catalytic Asymmetric Construction of Chiral Polysubstituted 3-Azabicyclo[3.1.1]heptanes by Copper-Catalyzed Stereoselective Formal [4π+2σ] Cycloaddition
2024 Standout
Cell death
2024 Standout
Works of Cathy Zhou being referenced
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
2015 Standout
The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma
2012
Author Peers
| Author | Genetics | PFM | Hematology | Immunology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Cathy Zhou | 1367 | 1127 | 442 | 486 | 42 | 1.4k | |
| ML Orme | 25 | 7 | 16 | 17 | 858 | ||
| M.M. Cooke | 1 | 3 | 4 | 61 | 20 | 542 | |
| Billy Koe | 7 | 342 | |||||
| P. Michael Conn | 2 | 7 | 2 | 31 | 10 | 455 | |
| Monic J. Stuart | 452 | 375 | 943 | 442 | 25 | 1.5k |
All Works
Login with ORCID to disown or claim papers
Loading papers...